Principal Investigator
Jonathan Trent
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20240634
Clinical Trial Summary
A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects with Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Bone and Soft Tissue Cancers
Contact Information
Phone Number
+1 (954) 8177628